What We're Reading: Page 342
Industry reads hand-picked by our editors
Mar 10, 2016
-
Stat
FDA deal with Amarin is unlikely to spark more off-label promotion
-
Washington Post
This drug is defying a rare form of leukemia — and it keeps getting pricier
-
FierceBiotech
Sarepta has a new date with an FDA AdCom for Duchenne drug eteplirsen
-
New York Times
Groups Scrutinize White House Plan to Cut Drug Costs in Medicare
Previous
